Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

AIkido Pharma SPEX

Healthcare Biotechnology
AIkido Pharma Inc is a United States-based biotechnology company. The company is engaged in the development of small-molecule anti-cancer therapeutics. The company's drug portfolio includes therapies for pancreatic cancer, acute myeloid leukemia (AML), and acute lymphoblastic leukemia (ALL).


NDAQ:SPEX - Post by User

AIkido Pharma
Bullboard Posts
User Avatar Image
(0)
•••
Post by Subchimes1on Mar 10, 2020 1:55pm
405 Views
Post# 30789420

Definitive agreement announced yesterday, @ $2.75,

Definitive agreement announced yesterday, @ $2.75,
Definitive agreement announced On March 9th, for 5.75 million, @$2.75, why are we trading below that today? Press release,  should close at or around March 11th, looks like its trading very cheap right now.
Bullboard Posts
Dealroom for high-potential pre-IPO opportunities